Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of trenibotulinumtoxinE for moderate to severe glabellar lines
jRCT2031240348Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2024
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial in glabellar furrowing comparing trenibotulinumtoxinE with placebo (2 arms). Started Oct 2024; status: completed.
02
Drugs
trenibotulinumtoxinE
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on jRCT2031240348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240348.